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  ABSTRACT 
 
THE RELATIONSHIP BETWEEN UNMETABOLIZED FOLIC ACID AND SERUM 
FOLATE CONCENTRATIONS AND CANCER RISK IN OLDER US ADULTS 
by 
Regine L. Baldauff 
 
Importance  Several studies have reported an increase in serum and unmetabolized folic 
acid levels since the implementation of folic acid fortification (January 1, 1998).  
However, the literature published during the post-folic acid fortification period is 
controversial with regards to the safety and potential risk for cancer in non-target 
populations.  
Objective  To study the association between unmetabolized folic acid and serum folate 
and cancer in older US adults. 
Design, Setting, and Participants  This is a cross sectional study using data from 
National Health and Nutrition Examination Surveys.  Among 700 participants with 
identified unmetabolized folic acid, 147 cases were reported a history of having cancer 
from 1999-2002.  Within the 7,981 subjects who had a recorded value for serum folate 
from 1999-2008; 1,459 reported a history of all cancer.  Among the 4,007 women who 
had a recorded value for serum folate between 1999-2008; 288 reported a history of 
breast cancer. 
Main Outcome Measures  Associations of unmetabolized folic acid and serum folate 
with all cancer and breast cancer was evaluated using a multivariable logistic regression 
analysis controlling for demographic and dietary intakes. 
	  Results  Men and women without unmetabolized folic acid were 0.7 times less likely to 
develop cancer.  Those over the age of sixty with the highest concentration of serum 
folate were 1.4 times more likely to have cancer than participants with lower serum folate 
concentrations.  Women over the age of sixty with the highest concentration of serum 
folate were 1.8 times more likely to have breast cancer compared to women with lower 
serum folate concentrations. 
Conclusions and Relevance  The presence of unmetabolized folic acid and high serum 
folate concentrations were related to an increased prevalence of cancer.  Further research 
is warranted to investigate the cause and effect relationship.   
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CHAPTER I 
 
THE RELATIONSHIP BETWEEN UNMETABOLIZED FOLIC ACID AND SERUM 
FOLATE CONCENTRATIONS AND CANCER RISK IN OLDER US ADULTS 
 
 
INTRODUCTION 
 
Folate, chemically known as polyglutamate, is found in dark green leafy 
vegetables, i.e. spinach and kale. Folic acid also known as monoglutamate is the synthetic 
form of folate and is found in all fortified foods and supplements containing folate in the 
United States (US)1.  The Food and Drug Administration (FDA) implemented folic acid 
fortification in January of 1998 with the intent of lowering the prevalence of neural tube 
defects in infants born in the US2.  Folate is the major methyl donor in one-carbon 
metabolic pathways throughout the body; and plays a key role in the development of 
precursors for the building of DNA, repair, and DNA methylation3.  Over the past decade 
during the post-fortification era, the research community has become concerned that the 
non-targeted population (i.e. men, children, and postmenopausal women) might be 
getting more folic acid than they need.  Additionally, studies have been implemented to 
address any potential consequences of excess folic acid intake by non-target populations.  
Most recently the focus has been on the increased consumption of folic acid and the 
occurrence of cancer.    
 Recently, researchers have raised the question of whether or not folate and 
unmetabolized folic acid plays a dual role in cancer, as both a cancer preventer and 
promoter1,4.  Due to the function folate plays in cell division and cellular growth, and 
stemming from its role as a cofactor in the synthesis of purines and thymidylate, and 
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nucleic acid synthesis, researchers have begun to question its involvement in cancer, 
helpful or harmful4?  When examining cancer cells and the accelerated rate at which they 
replicate and divide in comparison to healthy cells found in the body, removing folate 
sources and preventing folate metabolism has shown to inhibit tumor growth4.  This 
finding has created a platform for the use of antifolate drugs in cancer chemotherapy 
treatments4.  
 Multiple studies have been conducted in various fields of cancer development and 
treatment, and although the results are still controversial many have demonstrated a 
positive association between increased levels of serum folate and cancer incidences.  
Most notably, researchers have illustrated a relationship between the folic acid 
fortification era and a spike in colorectal cancer incidence in the US4,5.  The evidence 
from several recent clinical trials regarding colorectal cancer incidence rates, has shown a 
relationship between folic acid and cancer prevalence and pre-malignant lesions4.  A 
study conducted with postmenopausal women showed a relationship between high 
dietary folate intake and increased risks for breast cancer3.  The study also illuminated the 
need for a large population based study to assess the relationship between the folic acid 
fortification and breast cancer prevalence3.   
 The National Health and Nutrition Examination Survey (NHANES), was used in 
the current study to collect a nationally representative data set for serum folate 
concentrations, unmetabolized folic acid concentrations, and cancer prevalence.  
NHANES, monitored and carried out by the Center for Disease Control and Prevention 
(CDC) is a complex survey design used to collect nationally representative data for the 
following areas: demographics, socioeconomic, dietary, medical history, and laboratory 
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values from a diverse population, with the intent of monitoring the overall health status of 
the US popualtion6.  The current investigation is the first study to conduct a large-scale 
study using NHANES data to establish an association between folic acid supplementation 
and cancer risk in both men and women over the age of 60. 
Objective 
 
The purpose of this study was to assess the relationship between the folate status 
and cancer in older US adults using a nationally representative sample survey.  The 3 
specific aims of the study are to examine: 1) the relationship of unmetabolized folic acid 
with the prevalence of all cancer in older adults over the age of 60, 2) the effect of serum 
folate on all cancer in both men and women over the age of 60, and 3) the relationship 
between serum folate concentrations and breast in women over the age of 60 years in the 
US.  
Hypothesis 
 
We hypothesize is that serum folate status is related to an increased prevalence of 
both breast cancer and all cancer rates in both men and women over the age of sixty; 
additionally the presence of unmetabolized folic acid is related to an increased prevalence 
of cancer in older US adults.  
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CHAPTER II 
 
 
LITERATURE REVIEW 
 
Folate (polyglutamate), the natural vitamer is commonly found in dark green leafy 
vegetables, citrus fruits, legumes, shellfish, yeast, and liver7,8.  Folic acid 
(monoglutamate), is found in supplements and fortified foods such as grains, flours, and 
cereals9.  Folic acid chemically differs from its natural form, folate, existing in an 
oxidized state with only one conjugated glutamate residue4,7.  The differences between 
the chemical structures of folic acid and folate allows folic acid to have a higher 
bioavailability10 and absorb more rapidly across the intestines4,10.  Folate is part of the 
water-soluble B vitamin family, known as B97,8,9,11.  
In 1998, the Federal Food and Drug Administration (FDA) mandated fortification 
of all enriched flour2, grain, and cereal products with 140µg/100g of folic acid 2,7,12.  The 
mandatory fortification followed an announcement from the US Public Health Services 
recommending that all pregnant women and women of the child bearing age should 
consume 400µg of folic acid per day13, with an upper intake level (UL) of 1000µg/day for 
all populations7,13,14.  This recommendation was directed towards reducing neural tube 
defects in newborns13.  However, since folic acid fortification began it has been reported 
that the average folic acid intake is greater than 800µg/day, particularly in individuals 
consuming both fortified foods and daily supplements7.      
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Although the FDA has set an UL for folic acid intake13, there is not a bench mark 
for a safe upper limit regarding serum folate4,13.  Many have agreed within the scientific 
and medical communities that a serum folate concentrations above 45 nmol/L is 
considered significantly higher than standard physiological levels4.  Recently it has been 
reported that 23% of Americans have a serum folate concentration >45nmol/L since the 
implementation of folic acid fortification4.  Additionally, mandated folic acid fortification 
has lead to the tripling of the average serum folate level in populations across the US15.  
Mandatory folic acid fortification lead to an extremely high increase in folic acid 
consumption16 far beyond the intended target population4 and could potentially have 
adverse effects4,16.  
Over the past several years multiple studies have been conducted to evaluate the 
amount of folic acid intake after the fortification of folic acid began, and the effect folic 
acid fortification has had on the general population.  One of the more recent concerns is 
the finding of unmetabolized folic acid in an individual’s blood serum. Unmetabolized 
folic acid accumulates in an individuals blood serum upon a person consuming high 
amounts of folic acid; as their cellular metabolism becomes saturated with the vitamin it 
is unable to process and convert all of the ingested folic acid back to its reduced state, 
known as folate, to be utilized by one-carbon transfer reactions and DNA 
methylation1,17,18,.  The result is an excess of circulating folic acid that ultimately remains 
in its oxidized form in the blood1,17.  Unfortunately researchers only understand pieces 
regarding unmetabolized folic acid and its effects on the population1,19. Many researchers 
believe the growing level of unmetabolized folic acid is a safety concern and could be 
contributing to several biological illnesses, such as cancer1,17.   
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Folate is a required co-factor in cellular metabolism and plays a critical role in 
one-carbon transfers, DNA synthesis, repair and maintenance4,7,15,20.  One carbon 
transfers are vital for the building of nucleotides and methylation reactions7,20,21.  Most 
notably, folate is a required cofactor for the thymidylate synthesis reaction7; in this 
reaction deoxyuridine monophosphate (dUMP) is converted to thymidine monophosphate 
(dTMP) through a one carbon transfer to ultimately produce purines and thymidine 
nucleotides to be used in DNA synthesis7,9,11,15,16,20,21,22,23.   Furthermore, folate is vital for 
the remethylation of homocsysteine back to methionine; the carbon donor for S-
adenosylmethionine (SAM) a critical methyl donor for physiological methylation 
reactions, i.e. DNA methylation4,7,11,15,20,24.  The involvement of folate in DNA synthesis 
makes it an essential factor in DNA replication and cell division20.  Due to the importance 
of folate as a key player in cellular metabolism, and DNA synthesis7, current research 
suggests consuming high amounts of synthetic folate may enhance the proliferation of 
cancer cells and malignant tumors1. 
 Among researchers there is a debate over the belief of whether folic acid prevents 
the onset of diseases such as cancer or if it fuels the progression of the disease.  Many 
scientists believe folic acid insufficiency is cancer causing, because the depletion of folic 
acid within the body leads to a cascade of hindered one-carbon transfer reactions, and 
ultimately cellular metabolic processes become compromised, escalating to more severe 
outcomes: DNA instability, altered DNA methylation, and the inability to repair 
DNA11,25,26.  According to Jennings26, folic acid is a cancer preventer, emphasizing that 
defected DNA segments extracted from animal and cell experiments where folic acid was 
with-held, resembles the DNA found in cancer cells.  Research has also illustrated, when 
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cells are denied and depleted of folic acid the outcome results in DNA damage26.  In 
studies using rats, DNA damage from inadequate folic acid intake was indicated by DNA 
strand breakages within the rats white blood cells26.   
Researchers have illustrated folate deficiency leads to the break down of 
chromosomes due to the incorporation of uracil in the place of thymine during DNA 
synthesis8,15,22,27,28.  Additionally decreased methylation caused by a depletion of folate 
stores causing the over methylation of the promoter region in tumor suppressor genes 
leading to gene silencing and unregulated cancer cell development8,15,25,27,28.  Ultimately, 
the argument for folic acid being a cancer preventative lies in the following scientific 
postulate.  When an individual is folic acid deficient they deplete their folate stores, the 
biosynthetic pathways vital for DNA integrity are unable to function successfully, leading 
to an increased risk for tumor development25,29.   
 The discussion regarding folate as a tumor cell and cancer promoter is usually 
avoided due to the controversy created with the public health sector12.  According to 
Kim12, cancer cells grow at an accelerated rate, due to enhanced DNA replication and cell 
division.  When considering the pathways and essentialness of folate in the biosynthesis 
of DNA, enhanced folate status acts as an accelerant for tumor cell growth12.  Research 
has demonstrated when folate is removed hindering its pathways, DNA replication is 
reduced leading to a decrease in cancer cell proliferation12.  In experimental trials the 
depletion of folate has shown to prevent further development of pre-established 
malignant cells12.  Both animal based studies and clinical trials have illustrated that folate 
supplementation enhances cancer risk via fueling cancer progression when large doses of 
the vitamin are ingested after the development of malignant cells12.  In a study conducted 
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on mice inoculated with leukemia cells, excess folic acid given through diet expedited the 
cancer progression causing an increased mortality rate compared to the control group15.  
According to Baggott et. al.16, folic acid supplementation supports cancer development 
by enhancing the pool of nucleotides needed for DNA synthesis in abnormal cells.  
Furthermore, the current research supports the “acceleration phenomenon” which occurs 
when folic acid feeds pre-existing undiagnosed tumor cells5,12.  The danger associated 
with these findings from a public health prospective, is that it is essentially impossible to 
determine the onset of abnormal cell development12.  For individuals who are consuming 
large doses of folic acid, malignant and abnormal cells will flourish in the presence of 
high levels of folate available for their cells cellular metabolism12. 
 Since the early 20th century scientists have studied and linked folate with 
malignant formations and cancer related diseases14.  Baggott et. al.16 stated, “antifolates 
are the only antivitamins that are effective in cancer development.”  In the 1940’s, 
scientists hypothesized folate deficiency was the cause of acute leukemia, unfortunately 
treatment with folate failed causing an excitatory effect in the malignant cells among the 
patients14,15.   Following this discovery, researchers Heinle and Welch30 induced folate 
deficiency within their patients, ultimately inhibiting the progression of the malignant 
leukemia cancer cells14,15.   In 1947, Farber developed the first antifolate drug 
aminopterin; treatment with aminopterin lead to remission among children with 
leukemia14.  Since Farber’s discovery the field of antifolates as a chemotherapeutic agent 
has expanded and has become a primary treatment protocol for cancer diagnosis which 
now encompasses multiple classes of antifolates 14,31. 
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 Researchers have hypothesized that the damaging effects from folate (i.e. the 
proliferation of cancer cells) occurs most often in cases of high consumption of folic acid 
from both the intake of fortified foods and supplements32.  From a study conducted by 
Mason et. al.5, folic acid fortification was hypothesized to be a potential key factor in the 
reversal of the decrease in the number of cases seen in colorectal cancer in both the US 
and Canada5,24.  The results from their study indicated a 10% increase in colorectal 
cancer since the implementation of folic acid supplementation in the two countries24,31.  A 
recent study examining the relationship between prostate cancer prevalence and folic acid 
fortification illustrated the presence of prostate cancer in patients with higher levels of 
serum folate24.  Bistulfi et. al.31, reported on a study examining prostate cancer in men 
over the age of 50, and concluded that the occurrence of cancer in this subset of men was 
high while attributing the results to folic acid fortification and its accelerant effect on 
malignant cell growth. 
  According to recent data, breast cancer is the leading cause of cancer related 
mortalities in women living in the US33.  In light of these statistics, understanding and 
identifying major risk factors for breast cancer is crucial for both the prevention and 
treatment of breast cancer consumption33.  Scientists have reported a connection between 
breast cancer and high folic acid consumption34.  A link between folate and the estrogen 
receptor (ER) genes has been reported, indicating folate as a key participant in silencing 
the ER genes, leading to malignant cell formation34. The literature indicates folic acid 
may provide a protective effect for premenopausal women, but could pose a potential 
threat to postmenopausal women because they have decreased folate needs compared to 
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premenopausal women35.  The current data examining the association between folic acid 
and breast cancer is still inconclusive due to the number of conflicting results36.     
 Upon examining the literature there is a substantial concern regarding the folic 
acid fortification public health policy and its overall effect on the non-targeted 
population.  Currently the data conclusively indicates a substantially larger increase in 
folic acid intake in ”non-targeted” populations, which includes men and women past the 
“child-bearing” age.   In light of the controversial data currently available regarding folic 
acid and the development of cancer in the non-targeted populations, further research is 
warranted to further investigate the true underlying relationship between folic acid 
fortification and health risks for the general public.  
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CHAPTER III 
 
 
METHODS 
 
Study description and survey design 
 
 The National Health and Nutrition Examination Survey (NHANES) is conducted 
by the National Center for Health Statistics (NCHS), and an integral part of the Center for 
Disease Control and Prevention (CDC)6.   The NHANES program conducts surveys, 
interviews, and medical examinations to report critical health statistics for all populations 
in the United States on a yearly cycle6. NHANES utilized a stratified, multistage 
probability sample survey design to assess the US population health status37.  NHANES, 
surveyed and interviewed a nationally representative sample of individuals from a diverse 
collection of counties across the country, 15 of the same counties are sampled each year6.  
Individuals over the age of sixty, African Americans, and Hispanic were over sampled as 
per the design of the survey6.  All individuals who participated were requested to be 
surveyed, medically examined by a physician, and participate in the health questionnaires 
conducted by a team of trained interviewers6.  All health and survey questionnaires 
conducted during the initial part of the survey were carried out in the participants’ homes 
as part of the “house-hold” interview6.  A physician examined all individuals who 
participated in the surveys, and his or her body measurements were recorded in the 
NHANES Mobile Examination Centers (MECs)6.  
 In the current study, data from 2 NHANES cycles: NHANES 1999-200038 and 
2001-200239 were examined to evaluate the relationship between unmetabolized folic 
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acid and cancer risk (all cancer and breast cancer).  The detailed description for both of 
the 2 surveys methodologies and analytical guidelines are reported elsewhere40,41.   To 
examine the relationship between serum folate and both outcomes, all cancer and breast 
cancer, 5 NHANES cycles were analyzed: 1999-200038, 2001-200239, 2003-200442, 
2005-200643, 2007- 200844, to create a master data set 1999-2008.  The NHANES 1999-
2000 cycle was conducted between March 1999 and December 2000; during this time 
period a total of (12,160) individuals were screened, within the screened population 
(9,965) individuals were interviewed in their home, and (9,282) individuals were 
examined in the MEC45.  The NHANES 2001-2002 cycle was conducted between 
January 2001 and December 2002; during this time frame a total of (13,156) individuals 
were screened, of the screened individuals (11,039) individuals were interviewed in their 
homes, and (10,477) participants were examined in the MEC46.  
 The NHANES 2003-2004 cycle was conducted between January 2003 and 
December 2004; during this time frame a total of (12,761) individuals were screened, of 
the screened population (10,122) were interviewed in their homes, and (9,643) 
individuals were examined in the MEC47.  The NHANES 2005-2006 cycle was 
conducted between January 2005 and December 2006; a total of (12,862) individuals 
were screened, of the screened population (10,348) participants were interviewed in their 
homes, and (9,950) individuals were examined in the MEC48.  The NHANES 2007-2008 
cycle was conducted between January 2007 and December 2008; a total of (12,943) 
individuals were screened, of the screened population (10,149) participants were 
interviewed in their homes, and (9,762) individuals were examined in the MEC49. 
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The response rate for the 1999-2000 NHANES cycle in home interview was 
(82%), the response rate for the medical exam was (76%)45.  The response rate for the 
2001-2002 NHANES cycle in home interview was (84%), the response rate for the 
medical exam was (80%)46.  For the 2003-2004 NHANES cycle the in home interview 
response rate was (79%), and the medical exam response rate was (76%)47.  The in home 
response rate for the 2005-2006 NHANES cycle was (80.45%), and the medical exam 
response rate was (77.36%)48.  The response rate for the 2007-2008 NHANES cycle in 
home interview was (78.4%), the medical exam response rate was (75.4%)49. 
Current study methodology 
  
 The current study utilized the NHANES data for unmetabolized folic acid from 
the cycles 1999-2000, 2001-2002 to combine one large database 1999-2002.  The 
researcher focused on subjects 60 years or older in the analysis who had both a recorded 
unmetabloized folic acid concentration and had answered the medical condition 
questionnaire data concerning the presence of cancer for all cancers.  Serum folate 
concentration data was gathered from the NHANES cycles 1999-2000, 2001-2002, 2003-
2004, 2005-2006, 2007-2008, to create on large data file 1999-2008.  Subjects from this 
database were separated into 2 cohorts, all cancer and breast cancer risk.  The researchers 
used the medical condition questionnaire data concerning the presence for all cancer and 
breast cancer to analyze the association between serum folate concentrations, all cancer 
risk, breast cancer risk in US adults 60 years of age or older. 
Study sample 
 
 We excluded individuals from the analysis with missing values for sex, age, race-
ethnicity, unmetabolized folic acid concentrations, serum folate concentrations, and a 
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missing or “refused” to respond answers on the medical questionnaire for both, “all 
cancer” and “breast” cancer.  After the above exclusion criteria was applied the final 
study sample consisted of (2,682) individuals in the unmetabolized folic acid cohort (men 
=1320; women =1362), (7,981) subjects in the serum folate all cancer cohort (men = 
3974; women = 4007), and (4,007) women in the serum folate breast cancer cohort.  
 For the purpose of the data analysis age was classified into 2 categories (60-79 
years and ≥ 80 years).  Race-ethnicity was classified into 4 categories: (non-Hispanic 
white, non-Hispanic black, Hispanic, other).  Unmetabolized folic acid was analyzed for 
3 separate markers: methytetrahydrofolate (pmol/mL), folic acid (pmol/mL), and total 
folate (pmol/mL) for both “all cancer”, and “breast” cancer.  Serum folate was divided 
into 4 quartiles; the participants were categorized into one of the 4 quartiles based on 
their serum folate level (i.e. individuals with the lowest concentration of serum folate 
were categorized into the 1st quartile, and individuals with the highest serum folate 
concentrations were categorized into the 4th quartile).   
Measurements 
 
Unmetabolized Folic Acid 
 
 Unmetabolized folic acid concentrations were determined using the 
affinity/HPLC method and the electrochemical detection method50.  These methods were 
developed by NHANES at the Human Nutrition Research Center at Tufts University50. 
Total folate ascertained during this procedure is highly correlated (r2 = 0.93, p< 0.001) 
with total folate obtained by microbial assay50.  A detailed description of the laboratory 
methods is given elsewhere50,51. 
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Serum Folate 
 
Serum folate was ascertained by NHANES on participants aged 1 years of age 
older who were eligible for screening52.  NHANES used two separate methods during the 
studies time period: 1999-2008.  During the 4 NHANES data cycles 1999-2000, 2001-
2002, 2003-2004, and 2005-2006 the following laboratory methodology was utilized.   
The Bio-Rad Laboratories “Quantaphase II folate/vitamin B12” radioassy kit was used to 
quantify serum folate in all samples obtianed52.  During the NHANES 2007-2008 cycle 
participant’s serum folate was measured using the microbiologic assay53.  The assay was 
calibrated with 5-methlytetrahydrofolic acid from Epro53.  A detailed description of the 
laboratory methodology was reported elsewhere by NHANES51. 
 
Medical Conditions 
 
The medical conditions questionnaire data file provided personal interview data 
regarding an individual’s medical condition, for both their current and past medical 
history54.  Participant’s medical conditions were collected and reported using a 
questionnaire modeled after the US National Health Interview Survey54.  The medical 
conditions questionnaire used by NHANES collects a wide range of health related 
statistics for both children and adults54.  The survey was conducted during the in-home 
interview portion of the survey54.  The interviewers administer the questionnaire using 
the Computer Assisted Personal Interviewing – CAPI system55.  The information 
regarding the data processing and editing participants responses has been previously 
reported elsewhere by NHANES55,56. 
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Statistical analysis 
 
To account for the complex survey design of NHANES the SUDAAN statistical 
software Windows (version 8.0.2: Research triangle Institute, Research Triangle Park, 
NC) was used57.  According to the NHANES analytical and reporting guidelines sample 
weights, stratification, and clustering of the design was accounted for in the analysis to 
allow proper estimates and standard errors of the estimates to be obtained and prevent 
bias58.  SAS statistical software for Windows (version 9.1; SAS Institute Inc., Cary, NC) 
was also used in conjunction with SUDAAN to extract and analyze the original 
NHANES data files57.  Due to the unevenness of the distribution of the population sample 
across the examined categories, geometric means and standard errors of the geometric 
means were estimated using the Taylor Series Linearization method.  The geometric 
means and standard errors were used to describe the unmetabolized folic acid in both men 
and women based on age (60-79, ≥80), sex, and race (non-Hispanic White (NHW), non-
Hispanic Black (NHB), Mexican American/ Hispanic (MA/H) and others) for the study 
population.  The geometric means and standard errors of the geometric means are 
presented as means ± SE.   
To determine the risk of all cancer based on metabolized folic acid and serum 
folate concentrations, the prevalence rates (%) for individuals positive for cancer were 
calculated, and a logistic regression model was completed to estimate the odds ratio 
(OR), confidence interval (CI), and associated p-values to establish significance.  A t-test 
was conducted to determine the significance between the geometric means of 
unmetabolized folic acid in individuals positive for cancer and individuals who were 
cancer free.  To determine the risk for breast cancer among women >60, the prevalence 
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rate (%) of cancer for individuals who replied “yes” to the medical survey question 
“history of breast cancer” were calculated, and a logistic regression model was designed 
to estimate the odds ratio (OR), confidence (CI), and associated p-values to establish 
significance.  All p-values were set at p ≤ 0.05 for significance.   The researchers 
considered age, sex, race-ethnicity, poverty income ratio, and alcohol consumption as 
potential confounders.  The analysis models were adjusted for the confounders to 
ascertain a more precise relationship between the exposures (unmetabolized folic acid 
and serum folate) and the outcomes of interest (all cancer and breast cancer).   
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CHAPTER IV 
 
 
RESULTS 
 
Characteristics of the Study Population 
 The sample size for unmetabolized folic acid, all cancer, and breast cancer cohorts 
by gender, race-ethnicity, and age are presented in Table 1.  In the unmetabolized folic 
acid cohort 43.5% men and 56.5% women had measurable unmetabolized folic acid.  The 
highest percentage of unmetabolized folic acid for the ethnic category was in the non-
Hispanic white accounting for 82% of the sample size, while non-Hispanic black, 
Hispanic, and Other were by and large similar in sample size.  The subjects in the age 
group 60-79 years old represented the majority of the individuals with unmetabolized 
folic acid, 83.4%. 
 For the subjects in the all cancer cohort category, 44.2% were men and 55.8% 
were women.  The ethnic groups non-Hispanic black, Hispanic, and Other accounted for 
the smallest fraction of the sample population.  Non-Hispanic whites, represented the 
largest ethnic group in the study population, 81.8%.  The majority of the individuals 
classified by age were between 60-79 years old making up 82.5% of the cohort. 
 In the breast cancer cohort, non-Hispanic whites (81.3%) and subjects aged 
between 60-79 years old (80%) represented the largest proportion of the subjects.  While 
other ethnic groups and subjects ≥ 80 years old represented the smallest percentage of 
individuals analyzed. 
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Unmetabloized Folic Acid, Total Serum Folate, and All cancer Risk in the US 
 Data on unmetabolized folic acid and total serum folate concentrations in the US 
are presented in Table 2.  The mean unmetabolized folic acid concentrations between 
cancer free and cancer cohorts are not statistically significant.  Similarly, no significant 
difference was observed between cancer-free and cancer cohorts in serum folate and 
unmetabolized folic acid concentrations.       
 The likelihood of subjects with unmetabolized folic acid having cancer relative to 
individuals without unmetabolized folic acid is presented in Table 3.  In subjects with 
unmetabolized folic acid, the prevalence of cancer was 24% compared to 19.2% in 
subjects without unmetabolized folic acid.  In the unadjusted analysis individuals without 
the presence of unmetabolized folic acid were 0.76 times less likely to develop cancer 
compared to subjects with circulating unmetabolized folic acid (p < 0.045).  In the 
multivariate adjusted analysis, similar findings were observed (P = 0.05; OR: 0.76, 95% 
CI: 0.58, 1.00)  
Serum Folate Concentrations, All Cancer Risk, and Breast Cancer in the US 
 For the risk of all cancer and breast cancer according to serum folate 
concentrations; unadjusted ORs, multivariate adjusted ORs, and 95% CI are presented in 
Table 4 and Table 5, respectively.  The prevalence of all cancer was highest in serum 
folate quartile 4 at 24.7%.  In the unadjusted analysis, subjects in serum folate quartile 4 
are 1.62 times more likely to have cancer compared to quartile 1 (p < 0.000, 95% CI: 
1.30, 2.03).  Similar trends are seen in quartile 2 (OR: 1.34, 95% CI: 1.12, 1.60, p < 
0.002), but were not statistically significant for quartile 3.  In the multivariate adjusted 
analysis, subjects in quartile 4 were 1.42 times more likely to have cancer than 
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individuals in quartile 1 (p < 0.003, 95% CI: 1.13, 1.78).  A similar finding was noticed 
in quartile 2 (OR: 1.30, 95% CI: 1.08, 1.57, p < 0.006).  However, the results for quartile 
3 were not statistically significant when compared with the reference group, quartile 1 
(Table 4). 
 Subjects with the highest prevalence of breast cancer were reported in serum 
folate quartile 4 at 22.2%.   In the unadjusted analysis, individuals in serum folate quartile 
4 are 1.53 times more likely to have breast cancer compared to subjects in quartile 1 (p < 
0.004, 95% CI: 1.15, 2.02).  Similarly, in the multivariate adjusted analysis,  participants 
in serum folate quartile 4 were 1.86 times more likely to have cancer compared to the 
subjects in quartile 1 (p < 0.027, 95% CI: 1.08, 3.23). However, no significant difference 
was found between serum folate quartile 2 or quartile 3 when compared to serum folate 
quartile 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
21	  
Table 1. Baseline Characteristics for All Subjects Analyzed in The NHANES Cycles 
1999-20081 
   
 Sample size (n )2 (%) 
Unmetabolized Folic Acid3   
   
   
Sex   
 Men 1320 43.5% 
Women 1362 56.5% 
Race - ethnicity   
 Non-Hispanic white 1514 81.2% 
Non-Hispanic black 436 7.6% 
Hispanic 678 8.4% 
Other 54 2.8% 
Age   
 60-79 2086 83.4% 
≥ 79 596 16.6% 
 Sample size (n )4 (%) 
All Cancer5   
   
   
Sex   
 Men 3974 44.2% 
Women 4007 55.8% 
Race - ethnicity   
 Non-Hispanic white 4631 81.8% 
Non-Hispanic black 1358 7.9% 
Hispanic 1788 6.7% 
Other 204 3.5% 
Age   
 60-79 6222 82.5% 
≥ 79 1759 17.5% 
 Sample size (n )6 (%) 
Breast Cancer7   
   
   
Sex   
 Women 4007  
Race - ethnicity   
 Non-Hispanic white 2277 81.3% 
Non-Hispanic black 691 8.4% 
Hispanic 932 6.8% 
Other 107 3.5% 
Age   
 60-79 3072 80.0% 
≥ 79 935 20.0% 
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1 NHANES cycles 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008 were used 
to obtain information regarding unmetabolized folic acid, serum folate concentrations, all 
cancer, and breast cancer. 
2 Total sample size for unmetabolized folic acid study population (n = 2682). 
3 NHANES cycles 1999-2000 and 2001-2002 were combined into one large database to 
analyze the association between unmetabolized folic acid and all cancer risk US.  
4 Total sample size for the All cancer study population (n = 7981). 
5 NHANES cycles 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008 were 
combined into one large database to analyze the association between serum folate 
concentrations and all cancer risk in the US.  
6 Total sample size for the breast cancer study population (n = 4007). 
7 NHANES cycles 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008 were 
combined into one large database to analyze the association between serum folate 
concentrations and breast cancer risk in the US. 
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Table 2. Unmetabolized Folic Acid (UMFA)1 and Total Serum Folate Concentration for 
All Cancer Risk in The US2 
    	   	  
 Sample size3  Mean ± SE4 P-Value 	  
Unmetabolized Folic Acid pmol/L    	  
   
   
Total Cases5 2682 1.9 ± 0.17  	  
Cancer6 474            2.15 ± 0.36 0.70 	  
Cancer – Free7 2210 1.83 ± 0.16  	  
Total Folate pmol/L8    	  
   
   
Total Cases 2682 42.41 ± 0.81  	  
Cancer 474 43.16 ± 1.42 0.45 	  
Cancer - Free 2210 42.22 ± 0.80  	  
 
1 UMFA references unmetabolized folic acid. 
2 NHANES cycles 1999-2000 and 2001-2002 were combined to create one large database 
to analyze the association between unmetabolized folic acid, serum folate concentrations 
and all cancer risk.  
3 The total sample size for the study population (n = 2682). 
4 Geometric mean ± standard error (SE) of the geometric mean were used to account for 
the unevenness of the population distribution. 
5 Total cases include subjects from both the cancer group and cancer – free group. 
6 Cancer signifies the study population who reported having cancer. 
7 Cancer – Free signifies the study population who reported not having cancer. 
8 Total Folate pmol/mL includes both circulating unmetabolized folic acid and 
methyltetrahydrofolate (enzyme form of circulating folate). 
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Table 3. Unmetabolized Folic Acid (UMFA)1 and All Cancer Risk in The US2 
   
 UMFA – Positive3 UMFA – Negative4 
Total (n)5 700 1982 
Cancer Yes (n)6 147 327 
Prevalence (%) 21 16.5 
UNADJ OR (95% CI)7 1.00 0.76 (0.57, 0.99) 
P-Value - 0.045 
ADJ OR (95% CI)8 1.00 0.76 (0.58, 1.00) 
P-Value - 0.051 
 
1 UMFA references unmetabolized folic acid. 
2 NHANES cycles 1999-2000 and 2001-2002 were combined to create one large database 
to analyze the association between unmetabolized folic acid and all cancer risk in the US 
(n = 2682). 
3 UMFA – Positive indicates individuals who have measurable levels of unmetabolized 
folic acid. 
4 UMFA – Negative indicates individuals who do not have measurable levels of 
unmetabolized folic acid. 
5 Total (n) indicates the total sample size for both of the groups UMFA – Positive (n = 
700), and UMFA – Negative (n = 1982). 
6Cancer Yes indicates subjects in the study population who reported having cancer. 
7 UNADJ OR (95% CI) reports the unadjusted logistic regression odds ratio and 
corresponding confidence interval at a 95% significance level. 
8 ADJ OR (95% CI) reports the adjusted multivariate logistic regression odds ratio and 
corresponding confidence interval at a 95% significance level, the data was adjusted for 
the confounders: sex, age, poverty income ratio, alcohol and race-ethnicity. 
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Table 4. Serum Folate Concentrations and All Cancer Risk in the US1 
     
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total (n)2 2288 2146 1810 1737 
Cancer Yes (n)3 320 390 341 408 
Prevalence (%) 14 18.2 18.8 23.5 
UADJ OR (95% CI)4 1.00 1.34 (1.12, 1.60) 1.29 (1.06, 1.56) 1.42 (1.13, 2.03) 
P-Value - 0.002 0.011 <0.000 
ADJ OR (95% CI)5 1.00 1.30 (1.08, 1.57) 1.19 (0.98, 1.46) 1.42 (1.13, 1.78) 
P-Value - 0.006 0.08 0.003 
 
1 NHANES cycles 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008 were used 
to create one large database to analyze the association between serum folate 
concentrations and all cancer risk in the US. 
2 The total sample size for the study population (n = 7981). 
3 Cancer Yes indicates the subjects in the study population who have cancer. 
4 UNADJ OR (95% CI) reports the unadjusted logistic regression odds ratio and 
corresponding confidence interval at a 95% significance level. 
5 ADJ OR (95% CI) reports the adjusted multivariate logistic regression odds ratio and 
corresponding confidence interval at a 95% significance level, the data was adjusted for 
the confounders: sex, age, poverty income ratio, alcohol and race-ethnicity. 
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Table 5. Serum Folate Concentrations and Breast Cancer Risk in the US1 	   	   	   	   	  
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Total (n)2 933 1054 954 1006 
Cancer Yes (n)3 36 55 57 80 
Prevalence (%) 3.6 5.2 6 8 
UADJ OR (95% CI)4 1.00 1.26 (0.98, 1.62) 1.27 (0.97, 1.65) 1.53 (1.15, 2.02) 
P-Value - 0.08 0.08 0.004 
ADJ OR (95% CI)5 1.00 1.48 (0.96, 2.53) 1.56 (0.96, 2.53) 1.86 (1.08, 3.23) 
P-Value - 0.10 0.07 0.027 	  
1 NHANES cycles 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008 were used 
to create one large database to analyze the association between serum folate 
concentrations and breast cancer risk in the US. 
2 The total sample size for the study population (n = 4007). 
3 Cancer Yes indicates the subjects in the study population who have cancer. 
4 UNADJ OR (95% CI) reports the unadjusted logistic regression odds ratio and 
corresponding confidence interval at a 95% significance level. 
5 ADJ OR (95% CI) reports the adjusted multivariate logistic regression odds ratio and 
corresponding confidence interval at a 95% significance level the data was adjusted for 
the confounders: sex, age, poverty income ratio, alcohol and race-ethnicity. 
. 
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CHAPTER V 
 
 
DISSCUSSION 
 
In this report, we present the first data on the relationship between unmetabolized 
folic acid and serum folate concentrations on the prevalence of overall cancer and breast 
cancer in the US using data from NHANES 1999-2008.  When examining the 1999-2002, 
data, individuals without reported unmetabolized folic acid had a 24% reduction in the 
risk for developing all cancer (p = 0.05), compared to the subjects with reported 
unmetabolized folic acid, in both men and women.  The results for serum folate and all 
cancer risk indicated that subjects in the highest quartile are 1.4 times more likely to have 
cancer compared to the individuals in the lower quartiles (p<0.003).  Similar results were 
obtained for the relationship between breast cancer and serum folate concentrations.  
Women in the highest quartile reported being 1.9 times more likely to have breast cancer 
compared to the subjects in the lower quartiles (p<0.027).  
 Multiple studies have reported the presence of unmetabolized folic acid after the 
mandate to fortify cereal and unprocessed grains with folic acid in January 1998.  It has 
been reported that 78% of postmenopausal women in the US have unmetabolized folic 
acid, and it accounts for approximately 16% of all folate found in blood plasma4,23.  The 
data suggests that high unmetabolized folic acid causes a decrease in natural killer 
cytotoxicity leading to an increase in cancer by blocking the human body’s natural 
immune response to destroy the malignant cells, leading to the propagation of tumors16,23.  
According to Troen et al., there is a strong relationship between postmenopausal 
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women, unmetabolized folic acid and decreased natural killer cytotoxicity23.  The 
researchers postulate that the connection is significant because as individuals age there 
immune systems become weaker more susceptible to change, ultimately leading to 
diseases such as cancer23.     
 The body of evidence relating folic acid with cancer has reported conflicting 
results regarding folate status and all cancer risk.  Although the results are still debated, 
the research community agrees that the role of folate in cancer development depends 
strongly on the timing of an individual’s onset for folate consumption and the presence of 
malignant cell formation 4.  Scientists using animal research studies to examine colorectal 
cancer have illustrated that when cancer cells are introduced to high levels of folic acid, 
tumor cells grow at an increased rate29.  However during times of folate deficiency 
cellular metabolism is hindered, reducing the rate of DNA synthesis and replication, 
thereby decreasing the growth of tumors29.  Mason et al5, reported that the key role of 
folate in DNA synthesis is the same factor that makes it a growth factor for malignant 
cells.  The results from the current study supports the finding made by Mason et al.5, 
contributing to the spike in colorectal cancer seen in both the US and Canada in the late 
1990’s and early 2000’s to the introduction of folic acid fortification.   
The findings from 3 studies examining colorectal cancer cells in rats further 
confirm the finding that high levels of folic acid lead to cancer cell proliferation.  All of 
the experiments used rat models to explore the relationship between folate deficiency and 
cancer cell growth; their results indicated that in rats fed a folate deficient diet intestinal, 
colon, and rectal malignant growths were significantly decreased59, while rats fed average 
levels of folate (2.5 g/kg)60, had enhanced tumor growth60, showing a positive 
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relationship between folate intake and cancer outcomes59,61,60.  The researchers 
hypothesized that the role of folate in modifying DNA methylation is a possible factor for 
folate enhancing colorectal malignant growths59. These findings further support the data 
suggesting high levels of serum folate concentrations pose a potential threat to older 
population cohorts4. 
Studies based on high serum folate concentrations and the prevalence of prostate 
cancer in older men further support the finding of all cancer.  In a study by Tomaszewski 
et al.61, it was reported that high serum folate concentrations were detected in males 
diagnosed with prostate cancer, they concluded that male patients with high blood plasma 
folate concentrations often tested positive for the Ki67 maker for prostate cancer.  
According to a randomized control trial, subjects given folic acid had a 9.7% increased 
chance of developing prostate cancer over the follow-up period of 10 years, compared to 
the control group, these findings are in agreement with reports stating that the increase in 
prostate cancer in men over the age of 50 is fueled by folic acid supplementation62,31. 
The findings related to breast cancer risk studies in postmenopausal women are 
consistent with the literature, however the cited literature also explored several potential 
factors that could affect the relationship between folic acid intake and breast cancer.  The 
data from 2 large trails confers our findings; the cancer prevention study II reported 
women consuming the largest amount of folate showed a 12% higher prevalence of 
breast cancer when compared with the lowest intake group3.  The ovarian cancer 
screening trial reported that women consuming folic acid had a 20% increased incident of 
cancer, and individuals consuming the highest levels of total folate intake were associated 
with a 32% prevalence of breast cancer; they concluded that women who consume high 
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amounts of folate have also been found to have higher folic acid concentrations in their 
breast tissue and that this could trigger the production of the folate receptor α, causing an 
increased growth rate of malignant cells compared to women consuming less folic 
acid63,64,65.   
According to a meta-analysis, a recent study reported the relationship between 
increased plasma folate concentrations and the development of estrogen receptor beta 
negative (ERβ-) and estrogen receptor alpha positive beta negative (ERα+ β-) malignant 
breast formations7.  A second study concluding a possible association between increased 
folate consumption, breast cancer, and estrogen receptor positive (ER+)66 malignancies, 
but the same was not found in estrogen receptor negative (ER-)66,67,68 tumor cells7,66.  It 
has also been suggested that high folate status may be a contributing factor for cancer in 
women with a family history for breast cancer7.  Finally, two studies have reported a 
possible connection between folate receptor polymorphisms (MTHFR C677T) and 
(MTR2756GG) with increased folate intake and prevalence of breast cancer69,65,8. 
The current study has several strengths; first we used multiple cycles of NHANES 
to yield a larger sample size so that the results can be generalized to the population at 
large.  Second, laboratory values were used to report subject’s level of serum folate and 
unmetabolized folic acid eliminating any bias that could be present when using dietary 
intake data.  Finally, using serum folate concentrations allowed the researcher to establish 
a clearer understanding of the connection between folate intake and cancer risk.   
However there are several limitations within the study design that need to be 
discussed.  Because of the cross-sectional design used in this study the data shall not be 
looked at in terms of a cause and effect relationship. Secondly, due to the nature of the 
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secondary data used the researcher was unable to further investigate the association 
between the breast cancer status reported by the subjects (either ER+ or ER-) “not 
available” and folate intake.  
Conclusion 
 
 Antifolate drugs have been used since the 1940’s to combat the progression of 
cancer cells and block the cell receptors from binding with folate.  The main finding of 
folate is the proliferation in one-carbon transfer reactions to support DNA synthesis, 
repair, methylation and replication.  Individual in-vitro studies have shown the effect that 
folate deficiency has on hindering the growth and proliferation of established malignant 
tumor cells.  In 1948, Faber discovered the “acceleration phenomenon” when treating 
leukemia with folic acid, causing the cancer cells to grow at an extremely enhanced 
speed15,5.  Both the results from the current study and the literature support the concerns 
regarding subjects with undetectable malignant cells and the intake of folic acid.  
Individuals who are not part of the “target population” for the mandated folic acid 
fortification need to take special consideration with the amounts of folic acid they 
consume.  Recommendations to decrease and avoid excess folic acid intake should be 
considered for patients who have a history of conditions that are risk factors for cancer, 
especially, diseases of the intestines, colon, and prostate, previous history of cancer, or 
are currently undergoing cancer treatment.  Overall the literature supports the findings in 
the study; that older individuals in the US who have high folate status and unmetabolized 
folic acid are at a higher risk for all cancer, and specifically breast cancer.   
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